SELLAS Life Sciences (SLS) Cash from Operations Growth (3y) (2013 - 2026)
SELLAS Life Sciences (SLS) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.89 Bn | 1.78 Bn | - | 10.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.14% |
| Dec 31, 2025 | 1.44% |
| Sep 30, 2025 | -7.15% |
| Jun 30, 2025 | -8.36% |
| Mar 31, 2025 | -8.25% |
| Dec 31, 2024 | -12.86% |
| Sep 30, 2024 | -9.92% |
| Jun 30, 2024 | -25.50% |
| Mar 31, 2024 | -1.57% |
| Dec 31, 2023 | -50.50% |
| Sep 30, 2023 | -23.84% |
| Jun 30, 2023 | -30.80% |
| Mar 31, 2023 | -21.08% |
| Dec 31, 2022 | -7.25% |
| Sep 30, 2022 | -14.58% |
| Jun 30, 2022 | -7.36% |
| Mar 31, 2022 | -12.73% |
| Dec 31, 2021 | -2.99% |
| Sep 30, 2021 | 25.41% |
| Jun 30, 2021 | 8.04% |